WESTLAKE VILLAGE, Calif., June 05, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. Â (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations...
Expert recommendations focused on the diagnosis and management of genital psoriasis across age groups including pediatric, adult, and older populations This is the second published manuscript from the...
WESTLAKE VILLAGE, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. Â (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in...
WESTLAKE VILLAGE, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. Â (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations...
Q1 2026 net product revenue for ZORYVE ® (roflumilast) was $105.4 million, a 65% increase compared to Q1 2025, and a 17% decrease compared to Q4 2025 Continued strong demand for ZORYVE despite typical...
Barchart Research What to Expect from ARQT Earnings ARQT Generated May 5, 2026 Current Price $23.42 EPS Estimate $$-0.02 Consensus Rating Moderate Buy Average Move 7.56% Arcutis Reports Tomorrow Having...
Submission supported by data from INTEGUMENT-INFANT Phase 2 open-label study in infants aged 3 months to less than 24 months with mild to moderate atopic dermatitis Once-daily ZORYVE cream was well tolerated...
Strong recommendation with high certainty of clinical evidence underscores proven efficacy, safety, and tolerability of ZORYVE cream as a steroid-free topical phosphodiesterase type 4 (PDE4) inhibitor...
WESTLAKE VILLAGE, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. Â (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations...
Mr. Taylor brings a strong track record launching multiple high-profile therapies, most recently serving as Senior Vice President, Sales at Arcutis Biotherapeutics (Nasdaq: ARQT), where he led U.S. sales...